VUMERITY (Biogen Australia Pty Ltd)
Product name
VUMERITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
diroximel fumarate
Registration type
NCE/NBE
Indication
VUMERITY (enteric capsule) is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.